Literature DB >> 7667191

Controlled release of contraceptive steroids from biodegradable and injectable gel formulations: in vivo evaluation.

Z H Gao1, W R Crowley, A J Shukla, J R Johnson, J F Reger.   

Abstract

PURPOSE: The purpose of this study was to investigate in vivo biocompatibility, biodegradability and biological effects of contraceptive steroids, such as levonorgestrel and ethinyl estradiol, released from gels prepared with a combination of derivatized vegetable oil (Labrafil 1944 CS) and glyceryl ester of fatty acids (Precirol ATO 5).
METHODS: Biocompatibility, biodegradability, and in vivo effects of levonorgestrel and ethinyl estradiol were studied by histologic evaluation of rat tissue, visual estimate of changes in gel size, and assessment of drug effects on reproductive cyclicity of female rats, respectively, following subcutaneous injection of gel formulations.
RESULTS: Histological evaluation of the tissue samples following an injection of the gel revealed an inflammatory reaction for about 7 days, after which the tissues did not show any inflammatory response. Complete degradation of the gels containing 10% wax was observed between 5 and 6 weeks. Normal rat estrous cycles were completely blocked by the contraceptive steroids released from the gels. Gel formulations containing 0.25% w/w levonorgestrel were more effective in blocking the estrous cycle of female rats compared to the oil formulations containing an identical drug loading. The duration of the biological effect induced by levonorgestrel appears to be dose-related. The gel formulation containing 2.00% ethinyl estradiol was superior to oil formulation containing an identical drug loading in terms of controlling drug release and toxicity.
CONCLUSIONS: These observations suggest that Labrafil-Precirol gels are biocompatible and biodegradable. Moreover, controlled release of steroids is possible in vivo for a prolonged period of time.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7667191     DOI: 10.1023/a:1016261004230

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  9 in total

1.  Contraceptive vaginal ring--a rising star on the contraceptive horizon.

Authors:  K Buckshee; S Kumar; L Saraya
Journal:  Adv Contracept       Date:  1990-09

2.  Sustained-release of urease from a poloxamer gel matrix.

Authors:  K A Fults; T P Johnston
Journal:  J Parenter Sci Technol       Date:  1990 Mar-Apr

3.  Controlled release of a contraceptive steroid from biodegradable and injectable gel formulations: in vitro evaluation.

Authors:  Z H Gao; A J Shukla; J R Johnson; W R Crowley
Journal:  Pharm Res       Date:  1995-06       Impact factor: 4.200

4.  Clinical performance of a new levonorgestrel-releasing intrauterine device. A randomized comparison with a nova-T-copper device.

Authors:  C G Nilsson; T Luukkainen; J Diaz; H Allonen
Journal:  Contraception       Date:  1982-04       Impact factor: 3.375

5.  Sustained intrauterine release of d-norgestrel.

Authors:  T Luukkainen; C G Nilsson
Journal:  Contraception       Date:  1978-10       Impact factor: 3.375

6.  Intracervical release of levonorgestrel for contraception.

Authors:  H Kurunmäki; J Toivonen; P Lähteenmäki; T Luukkainen
Journal:  Contraception       Date:  1981-05       Impact factor: 3.375

7.  Sustained drug delivery systems II: Factors affecting release rates from poly(epsilon-caprolactone) and related biodegradable polyesters.

Authors:  C G Pitt; M M Gratzl; A R Jeffcoat; R Zweidinger; A Schindler
Journal:  J Pharm Sci       Date:  1979-12       Impact factor: 3.534

8.  Plasma levels of levonorgestrel in women during longterm use of norplant.

Authors:  H B Croxatto; S Díaz; P Miranda; K Elamsson; E D Johansson
Journal:  Contraception       Date:  1981-02       Impact factor: 3.375

9.  Long-term controlled delivery of levonorgestrel in rats by means of small biodegradable cylinders.

Authors:  D L Wise; H Rosenkrantz; J B Gregory; H J Esber
Journal:  J Pharm Pharmacol       Date:  1980-06       Impact factor: 3.765

  9 in total
  7 in total

1.  Preparation of PLGA microparticles by an emulsion-extraction process using glycofurol as polymer solvent.

Authors:  Anne Aubert-Pouëssel; Marie-Claire Venier-Julienne; Patrick Saulnier; Michelle Sergent; Jean-Pierre Benoît
Journal:  Pharm Res       Date:  2004-12       Impact factor: 4.200

2.  Tyrosine-based rivastigmine-loaded organogels in the treatment of Alzheimer's disease.

Authors:  Guillaume Bastiat; François Plourde; Aude Motulsky; Alexandra Furtos; Yvan Dumont; Rémi Quirion; Gregor Fuhrmann; Jean-Christophe Leroux
Journal:  Biomaterials       Date:  2010-05-15       Impact factor: 12.479

3.  Pharmaceutical organogels prepared from aromatic amino acid derivatives.

Authors:  Guillaume Bastiat; Jean-Christophe Leroux
Journal:  J Mater Chem       Date:  2009-04-28

4.  Localized delivery of ibuprofen via a bilayer delivery system (BiLDS) for supraspinatus tendon healing in a rat model.

Authors:  Brittany L Taylor; Dong Hwa Kim; Julianne Huegel; Harina A Raja; Sophie J Burkholder; Stephanie N Weiss; Courtney A Nuss; Louis J Soslowsky; Robert L Mauck; Andrew F Kuntz; Joseph Bernstein
Journal:  J Orthop Res       Date:  2020-04-07       Impact factor: 3.494

5.  Controlled Delivery of Salmon Calcitonin Using Thermosensitive Triblock Copolymer Depot for Treatment of Osteoporosis.

Authors:  Lindsey Lipp; Divya Sharma; Amrita Banerjee; Jagdish Singh
Journal:  ACS Omega       Date:  2019-01-14

6.  Enhanced Controlled Transdermal Delivery of Mexazolam Using Ethylene-vinyl Acetate.

Authors:  Cheong Weon Cho; Sang Chul Shin
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696

7.  Biodegradable Janus nanoparticles for local pulmonary delivery of hydrophilic and hydrophobic molecules to the lungs.

Authors:  Olga B Garbuzenko; Jennifer Winkler; M Silvina Tomassone; Tamara Minko
Journal:  Langmuir       Date:  2014-10-27       Impact factor: 3.882

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.